Several clinical trials have shown that immune checkpoint blockade is a promising approach for various types of cancer with high mutational burden, and that the combination of immune checkpoint blockade and conventional chemotherapy could have synergistic effects.

In the international trial AtTEnd, we aim to find out whether the addition of atezolizumab (Tecentriq^®) to chemotherapy and subsequent maintenance therapy using atezolizumab can improve patients’ prognoses, establish whether the treatment is safe and well tolerated, and evaluate its influence on quality of life.

This clinical trial will therefore provide vital information for the future treatment of patients with advanced endometrial cancer.

Further information on the AtTEnd trial can be found here.